Nomograms to predict survival and the risk for developing local or distant recurrence in patients with rectal cancer treated with optional short-term radiotherapy

Annals of Oncology

Volumn 26, Issue 5, 2015, Pages 928-935

  Van Gijn, Willem ^a   Van Stiphout, R G P M ^b,c   Van de Velde, C J H ^a   Valentini, V ^d   Lammering, G ^b   Gambacorta, M A ^d   Pahlman L ^e   Bujko, K ^f   Lambin, P ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d CATHOLIC UNIVERSITY   (Italy)

^e UPPSALA UNIVERSITY   (Sweden)

^f INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Local recurrence; Metastases; Nomogram; Prediction; Rectal cancer; Short term radiotherapy

Indexed keywords

ACCURACY; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HUMAN; LOCAL RECURRENCE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); MINIMAL RESIDUAL DISEASE; NOMOGRAM; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT IDENTIFICATION; PATIENT SELECTION; POSTOPERATIVE COMPLICATION; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM ABDOMINOPERINEAL RESECTION; RECTUM ANTERIOR RESECTION; RECTUM CANCER; RECURRENCE RISK; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SURGICAL TECHNIQUE; SURVIVAL RATE; TREATMENT DURATION; VALIDATION PROCESS; ADJUVANT RADIOTHERAPY; ADVERSE EFFECTS; DECISION SUPPORT SYSTEM; EUROPE; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RECTAL NEOPLASMS; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; DECISION SUPPORT TECHNIQUES; EUROPE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NOMOGRAMS; PATIENT SELECTION; PROPORTIONAL HAZARDS MODELS; RADIATION DOSAGE; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECTAL NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84929096188     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv023     Document Type: Article

References (28)

1. Folkesson J, Birgisson H, Pahlman L et al. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 2005; 23(24): 5644-5650.
2. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery-the clue to pelvic recurrence? Br J Surg 1982; 69(10): 613-616.
3. van Gijn W, Marijnen CA, Nagtegaal ID et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011; 12(6): 575-582.
4. Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006; 93(10): 1215-1223.
5. Starzewski JJ, Pajak JT, Pawelczyk I et al. The radiation-induced changes in rectal mucosa: hyperfractionated vs. hypofractionated preoperative radiation for rectal cancer. Int J Radiat Oncol Biol Phys 2006; 64(3): 717-724.
6. Guillem JG, Diaz-Gonzalez JA, Minsky BD et al. cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol 2008; 26(3): 368-373.
7. Kachnic LA, Hong TS, Ryan DP. Rectal cancer at the crossroads: the dilemma of clinically staged T3, N0, M0 disease. J Clin Oncol 2008; 26(3): 350-351.
8. Ngan SY, Burmeister B, Fisher RJ et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 2012; 30(31): 3827-3833.
9. Siegel R, Burock S, Wernecke KD et al. Preoperative short-course radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multicentre prospectively randomised study of the Berlin Cancer Society. BMC Cancer 2009; 9: 50.
10. Willett CG, Badizadegan K, Ancukiewicz M, Shellito PC. Prognostic factors in stage T3N0 rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy? Dis Colon Rectum 1999; 42(2): 167-173.
11. Merchant NB, Guillem JG, Paty PB et al. T3N0 rectal cancer: results following sharp mesorectal excision and no adjuvant therapy. J Gastrointest Surg 1999; 3 (6): 642-647.
12. Faerden AE, Naimy N, Wiik P et al. Total mesorectal excision for rectal cancer: difference in outcome for low and high rectal cancer. Dis Colon Rectum 2005; 48 (12): 2224-2231.
13. Peeters KC, Marijnen CA, Nagtegaal ID et al. The TME trial after a median followup of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007; 246(5): 693-701.
14. Ferenschild FT, Dawson I, de Graaf EJ et al. Preoperative radiotherapy has no value for patients with T2-3, N0 adenocarcinomas of the rectum. Dig Surg 2009; 26(4): 291-296.
15. Pepe MS. Receiver operating characteristic methodology. J Am Stat Assoc 2000; 95(449): 308-311.
16. Shariat SF, Capitanio U, Jeldres C, Karakiewicz PI. Can nomograms be superior to other prediction tools? BJU Int 2009; 103(4): 492-495; discussion 5-7.
17. den Dulk M, Marijnen CA, Putter H et al. Risk factors for adverse outcome in patients with rectal cancer treated with an abdominoperineal resection in the total mesorectal excision trial. Ann Surg 2007; 246(1): 83-90.
18. Quirke P, Steele R, Monson J et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 2009; 373(9666): 821-828.
19. Taylor FG, Quirke P, Heald RJ et al. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. Ann Surg 2011; 253(4): 711-719.
20. Petersen SH, Harling H, Kirkeby LT et al. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev 2012; 3: CD004078.
21. Hong YS, Nam BH, Kim KP et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol 2014; 15(11): 1245-1253.
22. Glynne-Jones R, Counsell N, Quirke P et al. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann Oncol 2014; 25(7): 1356-1362.
23. Primrose JN, Perera R, Gray A et al. Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial. JAMA 2014; 311(3): 263-270.
24. Fahy BN. Follow-up after curative cancer surgery: understanding costs and benefits. Ann Surg Oncol 2014; 21(3): 731-732.
25. Burton S, Brown G, Daniels IR et al. MRI directed multidisciplinary team preoperative treatment strategy: the way to eliminate positive circumferential margins? Br J Cancer 2006; 94(3): 351-357.
26. He Y, Van't Veer LJ, Mikolajewska-Hanclich I et al. PIK3CA mutations predict local recurrences in rectal cancer patients. Clin Cancer Res 2009; 15(22): 6956-6962.
27. Li T, Liao X, Lochhead P et al. SMO expression in colorectal cancer: associations with clinical, pathological, and molecular features. Ann Surg Oncol 2014; 21(13): 4164-4173.
28. van de Velde CJ, Aristei C, Boelens PG et al. EURECCA colorectal: multidisciplinary mission statement on better care for patients with colon and rectal cancer in Europe. Eur J Cancer 2013; 49(13): 2784-2790.